GlassScriptPhysician profile
Kaitlyn Collins
NPI 1770104366
$5,383.55
in general payments reported to CMS, 2019-2025
47 companies · $577 in 2025
The $577 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,389 · 2022: $1,326 · 2023: $1,121 · 2024: $971 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,668.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,095.27 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $670.12 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $559.25 | 2021-2023 | |
| Medtronic, INC. | $486.58 | 2021-2025 | Minimed 780g |
| Amgen INC. | $455.79 | 2021-2025 | Tepezza, Blincyto |
| Xeris Pharmaceuticals, INC. | $427.17 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Corcept Therapeutics | $212.02 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $155.62 | 2021-2025 | Isturisa, Signifor Lar |
| Antares Pharma, INC. | $154.30 | 2022 | |
| Amneal Pharmaceuticals LLC | $105.04 | 2021-2025 | Unithroid |
| Ultragenyx Pharmaceutical INC. | $77.43 | 2021-2024 | Crysvita |
| Sanofi-Aventis U.S. LLC | $67.10 | 2021 | |
| Nevro Corp. | $66.41 | 2022-2023 | Senza |
| Ibsa Pharma INC. | $54.61 | 2021-2022 | |
| Abbott Laboratories | $53.55 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlyn Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.